First elected: 8th June 2017
Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.
e-Petitions are administered by Parliament and allow members of the public to express support for a particular issue.
If an e-petition reaches 10,000 signatures the Government will issue a written response.
If an e-petition reaches 100,000 signatures the petition becomes eligible for a Parliamentary debate (usually Monday 4.30pm in Westminster Hall).
These initiatives were driven by Bambos Charalambous, and are more likely to reflect personal policy preferences.
MPs who are act as Ministers or Shadow Ministers are generally restricted from performing Commons initiatives other than Urgent Questions.
Bambos Charalambous has not been granted any Urgent Questions
Bambos Charalambous has not been granted any Adjournment Debates
A Bill to make provision for or in connection with the relief of debts of certain developing countries.
A Bill to make provision about children's access to medical services; and for connected purposes.
A Bill to make provision about children’s access to medical treatment; and for connected purposes.
The Bill failed to complete its passage through Parliament before the end of the session. This means the Bill will make no further progress. A Bill to require the provision of comprehensive palliative care to those with terminal illnesses, including adults over the age of 60; to require certain public bodies to co-operate with hospices in the provision of palliative care; to make provision for support for those caring for individuals with a terminal illness; and for connected purposes.
Powers of Attorney Bill 2024-26
Sponsor - Fabian Hamilton (Lab)
Breast Screening Bill 2021-22
Sponsor - Steve Brine (Con)
Wellbeing of Future Generations (No. 2) Bill 2019-21
Sponsor - Caroline Lucas (Green)
Sexual Offences (Sports Coaches) Bill 2019-21
Sponsor - Tracey Crouch (Con)
Disabled Facilities Grants (Review) Bill 2019-21
Sponsor - Liz Twist (Lab)
Compulsory Purchase and Planning Bill 2017-19
Sponsor - Emma Hardy (Lab)
Smoking Prohibition (National Health Service Premises) Bill 2017-19
Sponsor - Tracy Brabin (LAB)
National Health Service Bill 2017-19
Sponsor - Eleanor Smith (Lab)
I refer the hon. Member to the reply given to the hon. Member for Islington North, Jeremy Corbyn, on 23 July 2024, PQ 591.
The Department is working hard with industry to help resolve intermittent supply issues with some epilepsy medications. As a result of ongoing activity and intensive work, including directing suppliers to expedite deliveries, some issues, including with some carbamazepine, lamotrigine, and oxcarbazepine presentations, have been resolved.
We are aware of an ongoing supply issue with all strengths of topiramate tablets, with the resupply date to be confirmed. Other manufacturers of topiramate tablets can meet the increased demand during this time.
The Department is aware of supply constraints with one supplier of amantadine 100 milligram capsules used in the management of Parkinson’s Disease, however stocks remain available from alternative suppliers to cover demand. The Department have also been notified of a discontinuation of apomorphine (APO-go PFS) 50 milligram/10 milligram pre-filled syringes from April 2025, used in the treatment of Parkinson's disease patients. Alternative formulations of apomorphine remain available for patients, and management guidance has been issued to the National Health Service.
The Department has also been working hard with industry and NHS England to help resolve the supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are affecting the United Kingdom and other countries around the world. As a result of intensive work, some issues have been resolved and all strengths of lisdexamfetamine, atomoxetine capsules, and guanfacine prolonged-release tablets are now available.
We are continuing to work to resolve the remaining issues for methylphenidate prolonged-release tablets. We are engaging with all suppliers of methylphenidate prolonged-release tablets to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term. To improve supply and resilience, we are working with prospective new suppliers of methylphenidate prolonged-release tablets to expand the UK’s supplier base.
In collaboration with NHS England’s national ADHD data improvement plan, we plan to combine modelling for future growth forecasts, which will be shared with industry to improve demand forecasting for ADHD medicines.